Alzamend Neuro ALZN
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Business overview of Alzamend Neuro (ALZN)
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
Key Insights
Critical company metrics and information
Latest Closing Price
$0.76Market Cap
$5.01 MillionPrice-Earnings Ratio
-0.05Total Outstanding Shares
5.43 Million SharesTotal Employees
7Dividend
No dividendIPO Date
June 15, 2021SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQType
Common StockHeadquarters
3500 lenox rd. ne, Atlanta, GA, 30326Homepage
https://www.alzamend.com
Historical Stock Splits
If you bought 150 shares of ALZN before October 31, 2023, you'd have 1 share today.
| Execution Date | Split Amount |
|---|---|
| July 16, 2024 | 1-for-10 (Reverse Split) |
| October 31, 2023 | 1-for-15 (Reverse Split) |
Cash Flow Statement
November 1, 2023 to October 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities, Continuing | $-7.91 Million |
| Net Cash Flow From Investing Activities | $4.67 Million |
| Net Cash Flow From Operating Activities | $-7.91 Million |
| Net Cash Flow From Investing Activities, Continuing | $4.67 Million |
| Net Cash Flow From Financing Activities | $11.90 Million |
| Net Cash Flow From Financing Activities, Continuing | $11.90 Million |
Income Statement
November 1, 2023 to October 31, 2024
| Metric | Value |
|---|---|
| Nonoperating Income/Loss | $-19,454 |
| Preferred Stock Dividends And Other Adjustments | $0 |
| Net Income/Loss Attributable To Noncontrolling Interest | $7.07 Million |
| Basic Earnings Per Share | $-14.84 |
| Diluted Earnings Per Share | $-14.84 |
| Other Operating Expenses | $3.22 Million |
Comprehensive Income
November 1, 2023 to October 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss | $1.16 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss Attributable To Parent | $1.16 Million |
| Other Comprehensive Income/Loss | $0 |
Balance Sheet
November 1, 2023 to October 31, 2024
| Metric | Value |
|---|---|
| Current Liabilities | $1.25 Million |
| Assets | $5.01 Million |
| Noncurrent Liabilities | $0 |
| Equity | $3.75 Million |
| Liabilities And Equity | $5.01 Million |
| Fixed Assets | $240,976 |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Recent Headlines From The Web
Latest news, press releases, and media coverage about ALZN from trusted financial sources
ⓒ 2025 Financhle. All Rights Reserved.